Davidson Kempner Capital Management LP Abb Vie Inc. Transaction History

Davidson Kempner Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $49.9 Million - $55.6 Million	-474,537 Reduced 72.91%	176,325 $19.9 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $21.6 Million - $23.8 Million	211,557 Added 48.16%	650,862 $70.4 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $104 Million - $141 Million	-1,297,902 Reduced 74.71%	439,305 $47.1 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $104 Million - $122 Million	1,207,007 Added 227.65%	1,737,207 $152 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $14.7 Million - $19.7 Million	200,600 Added 60.86%	530,200 $52.1 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $21.3 Million - $32.2 Million	329,600 New	329,600 $25.1 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Davidson Kempner Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Davidson Kempner Capital Management LP with notifications on news.